Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cernuda-Morollón, E.
Right arrow Articles by Pérez-Sala, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cernuda-Morollón, E.
Right arrow Articles by Pérez-Sala, D.
J Am Soc Nephrol 13:2223-2231, 2002
© 2002 American Society of Nephrology

PPAR Agonists Amplify iNOS Expression While Inhibiting NF-{kappa}B: Implications for Mesangial Cell Activation by Cytokines

Eva Cernuda-Morollón*, Fernando Rodríguez-Pascual*, Peter Klatt{dagger}, Santiago Lamas* and Dolores Pérez-Sala*

*Department of Protein Structure and Function, Centro de Investigaciones Biológicas, C.S.I.C. and Instituto Reina Sofía de Investigaciones Nefrológicas, Madrid, Spain; and {dagger}Centro Nacional de Biotecnología, C.S.I.C., Madrid, Spain.

Correspondence to Dr. Dolores Pérez-Sala, Departamento de Estructura y Función de Proteínas, Velázquez, 144, 28006 Madrid, Spain. Phone: 34-91-5611800, ext. 4402; Fax: 34-91-5627518; E-mail: dperezsala{at}cib.csic.es

ABSTRACT. In acute inflammation, the transcription factor NF-{kappa}B is activated and increases the expression of multiple pro-inflammatory genes. Agonists of peroxisome proliferator activated receptors (PPAR) have been reported to exert antiinflammatory effects in various systems. In keeping with such an antiinflammatory role, it was found that several PPAR agonists, including Wy14,643, clofibrate, carbaprostacyclin, and ciglitazone inhibited NF-{kappa}B activity and increased I{kappa}B{alpha} levels in cytokine-stimulated mesangial cells (MC). Activation of NF-{kappa}B has been found to be crucial to the cytokine-elicited expression of inducible nitric oxide synthase (iNOS). Despite the inhibitory effect of PPAR agonists on NF-{kappa}B activity, this study provides experimental data demonstrating that these agonists amplify cytokine-elicited NO generation in MC, potentiating iNOS protein expression approximately threefold. The upregulation of iNOS expression occurred at the mRNA level and apparently did not result from iNOS mRNA stabilization. Clofibrate and ciglitazone amplified the cytokine-elicited stimulation of a 16-Kb human iNOS promoter construct in stably transfected MC, suggesting that PPAR agonists potentiate iNOS induction through transcriptional mechanisms. MC express all three PPAR proteins. However, iNOS potentiation did not correlate with increased PPAR activity. In addition, Wy14,643-induced amplification of cytokine-elicited iNOS levels also occurred in RAW264.7 macrophages and in human epithelial Caco-2 and HT-29 cells. The observation that these epithelial cell lines express an inactive, truncated PPAR{alpha} variant suggests that a classical PPAR{alpha} agonist, such as Wy14,643, may act through PPAR{alpha}-independent mechanisms. In conclusion, these results show that, despite reducing NF-{kappa}B activity, PPAR agonists may amplify the expression of certain NF-{kappa}B–dependent genes that are relevant to the inflammatory process, like iNOS.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Y.-J. Chen and J. Quilley
Fenofibrate Treatment of Diabetic Rats Reduces Nitrosative Stress, Renal Cyclooxygenase-2 Expression, and Enhanced Renal Prostaglandin Release
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 658 - 663.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. H. Napimoga, S. M. Vieira, D. Dal-Secco, A. Freitas, F. O. Souto, F. L. Mestriner, J. C. Alves-Filho, R. Grespan, T. Kawai, S. H. Ferreira, et al.
Peroxisome Proliferator-Activated Receptor-{gamma} Ligand, 15-Deoxy-{Delta}12,14-Prostaglandin J2, Reduces Neutrophil Migration via a Nitric Oxide Pathway
J. Immunol., January 1, 2008; 180(1): 609 - 617.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z. Yousefipour, H. Hercule, L. Truong, A. Oyekan, and M. Newaz
Ciglitazone, a Peroxisome Proliferator-Activated Receptor {gamma} Inducer, Ameliorates Renal Preglomerular Production and Activity of Angiotensin II and Thromboxane A2 in Glycerol-Induced Acute Renal Failure
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 461 - 468.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
V. Chintalgattu, G. S. Harris, S. M. Akula, and L. C. Katwa
PPAR-{gamma} agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts
Cardiovasc Res, April 1, 2007; 74(1): 140 - 150.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
A. Klopotek, F. Hirche, and K. Eder
PPAR{gamma} Ligand Troglitazone Lowers Cholesterol Synthesis in HepG2 and Caco-2 Cells via a Reduced Concentration of Nuclear SREBP-2
Experimental Biology and Medicine, September 1, 2006; 231(8): 1365 - 1372.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Zhao, J. E. Quigley, J. Yuan, M.-H. Wang, Y. Zhou, and J. D. Imig
PPAR-{alpha} activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2187 - H2195.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. Stamatakis, F. J. Sanchez-Gomez, and D. Perez-Sala
Identification of Novel Protein Targets for Modification by 15-Deoxy-{Delta}12,14-Prostaglandin J2 in Mesangial Cells Reveals Multiple Interactions with the Cytoskeleton
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 89 - 98.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C.-H. Wang, S.-H. Li, R. D. Weisel, P. W. M. Fedak, A. Hung, R.-K. Li, V. Rao, K. Hyland, W.-J. Cherng, L. Errett, et al.
Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R299 - R304.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
F. J. Sanchez-Gomez, E. Cernuda-Morollon, K. Stamatakis, and D. Perez-Sala
Protein Thiol Modification by 15-deoxy-{Delta}12,14-Prostaglandin J2 Addition in Mesangial Cells: Role in the Inhibition of Pro-inflammatory Genes
Mol. Pharmacol., November 1, 2004; 66(5): 1349 - 1358.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Perez-Sala, E. Cernuda-Morollon, and F. J. Canada
Molecular Basis for the Direct Inhibition of AP-1 DNA Binding by 15-Deoxy-{Delta}12,14-prostaglandin J2
J. Biol. Chem., December 19, 2003; 278(51): 51251 - 51260.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. Xu, Y. Fu, and A. Chen
Activation of peroxisome proliferator-activated receptor-{gamma} contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth
Am J Physiol Gastrointest Liver Physiol, June 9, 2003; 285(1): G20 - G30.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP